Sp1202
PANEL DISCUSSION
Date
May 9, 2023
Explore related products in the following collection:
Society: AGA
Talks on the blood based screening test clinical trial results that will occur in 2022 and 2023 (ECLIPSE, PREEMPT, BLUE-C) and effects on clinical care; updates on multi-cancer early detection test; emerging screening tests (Oncoguard, Colonosight, etc). This session will provide expert guidance on the tests and their appropriate use in clinical care. LIVE STREAM SESSION
Talks on the blood based screening test clinical trial results that will occur in 2022 and 2023 (ECLIPSE, PREEMPT, BLUE-C) and effects on clinical care; updates on multi-cancer early detection test; emerging screening tests (Oncoguard, Colonosight, etc). This session will provide expert guidance on the tests and their appropriate use in clinical care. LIVE STREAM SESSION
Presenters
Fred Hutchinson Cancer Research Center
University of Michigan
Tracks
Related Products
AGA Biomarkers for Early Detection of GI Cancers
SOCIETY: AGA
ITS TOO EARLY TO LENGTHEN SURVEILLANCE INTERNALS
Review updates and current considerations in colon cancer screening and surveillance related topics…
EMERGING SCREENING TESTS FOR LIVER CANCER SCREENING--ABBREVIATED MRI, BLOOD BASED ASSAYS, NEW PROTEIN BIOMARKER PANELS, ETC
Talks on the blood based screening test clinical trial results that will occur in 2022 and 2023 (ECLIPSE, PREEMPT, BLUE-C) and effects on clinical care; updates on multi-cancer early detection test; emerging screening tests (Oncoguard, Colonosight, etc)…
COLONOSCOPY ADHERENCE IN A MULTI-CENTER STUDY OF COLORECTAL CANCER (CRC) SCREENING
BACKGROUND: The Nordic-European Initiative on Colorectal Cancer (NordICC) Study highlighted the impact of adherence on the effectiveness of colonoscopy at reducing CRC incidence and mortality…
